Serum Neprilysin and Recurrent Admissions in Patients With Heart Failure
BackgroundOur aim was to evaluate the association between the soluble form of neprilysin (sNEP) levels and long‐term all‐cause, cardiovascular, and acute heart failure (AHF) recurrent admissions in an ambulatory cohort of patients with heart failure. sNEP has emerged as a new biomarker with promisin...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2017-08-01
|
| Series: | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease |
| Subjects: | |
| Online Access: | https://www.ahajournals.org/doi/10.1161/JAHA.117.005712 |
| _version_ | 1818312003628826624 |
|---|---|
| author | Julio Núñez Eduardo Núñez Jaume Barallat Vicent Bodí Gema Miñana M. Cruz Pastor Juan Sanchis Josep Lupón Antoni Bayes‐Genis |
| author_facet | Julio Núñez Eduardo Núñez Jaume Barallat Vicent Bodí Gema Miñana M. Cruz Pastor Juan Sanchis Josep Lupón Antoni Bayes‐Genis |
| author_sort | Julio Núñez |
| collection | DOAJ |
| description | BackgroundOur aim was to evaluate the association between the soluble form of neprilysin (sNEP) levels and long‐term all‐cause, cardiovascular, and acute heart failure (AHF) recurrent admissions in an ambulatory cohort of patients with heart failure. sNEP has emerged as a new biomarker with promising implications for prognosis and therapy in patients with heart failure. Reducing the recurrent admission rate of heart failure patients has become an important target of public health planning strategies. Methods and ResultsWe measured sNEP levels in 1021 consecutive ambulatory heart failure patients. End points were the number of all‐cause, cardiovascular, and AHF hospitalizations during follow‐up. We used covariate‐adjusted incidence rate ratios to identify associations. At a median follow‐up of 3.4 years (interquartile range: 1.8–5.7), 391 (38.3%) patients died, 477 (46.7%) patients had 1901 all‐cause admissions, 324 (31.7%) patients had 770 cardiovascular admissions, and 218 (21.4%) patients had 488 AHF admissions. The medians for sNEP and amino‐terminal pro‐brain natriuretic peptide were 0.64 ng/mL (interquartile range: 0.39–1.22) and 1248 pg/mL (interquartile range: 538–2825), respectively. In a multivariate setting, the adjusted incidence rate ratios for the top (>1.22 ng/mL) versus the bottom (≤0.39 ng/mL) quartiles of sNEP were 1.37 (95% confidence interval: 1.03–1.82), P=0.032; 1.51 (95% confidence interval: 1.10–2.06), P=0.010; and 1.51 (95% confidence interval: 1.05–2.16), P=0.026 for all‐cause, cardiovascular, and AHF admissions, respectively. ConclusionsElevated sNEP levels predicted an increased risk of recurrent all‐cause, cardiovascular, and AHF admissions in ambulatory patients with heart failure. |
| first_indexed | 2024-12-13T08:10:57Z |
| format | Article |
| id | doaj.art-09e87a7a0d4d4658a3e87f99a60126e6 |
| institution | Directory Open Access Journal |
| issn | 2047-9980 |
| language | English |
| last_indexed | 2024-12-13T08:10:57Z |
| publishDate | 2017-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease |
| spelling | doaj.art-09e87a7a0d4d4658a3e87f99a60126e62022-12-21T23:54:13ZengWileyJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease2047-99802017-08-016810.1161/JAHA.117.005712Serum Neprilysin and Recurrent Admissions in Patients With Heart FailureJulio Núñez0Eduardo Núñez1Jaume Barallat2Vicent Bodí3Gema Miñana4M. Cruz Pastor5Juan Sanchis6Josep Lupón7Antoni Bayes‐Genis8Cardiology Department, Hospital Clínico Universitario, INCLIVA, Valencia, SpainCardiology Department, Hospital Clínico Universitario, INCLIVA, Valencia, SpainBiochemistry Service, Hospital Universitari Germans Trias i Pujol, Badalona, SpainCardiology Department, Hospital Clínico Universitario, INCLIVA, Valencia, SpainCardiology Department, Hospital Clínico Universitario, INCLIVA, Valencia, SpainBiochemistry Service, Hospital Universitari Germans Trias i Pujol, Badalona, SpainCardiology Department, Hospital Clínico Universitario, INCLIVA, Valencia, SpainCIBER Cardiovascular, Madrid, SpainCIBER Cardiovascular, Madrid, SpainBackgroundOur aim was to evaluate the association between the soluble form of neprilysin (sNEP) levels and long‐term all‐cause, cardiovascular, and acute heart failure (AHF) recurrent admissions in an ambulatory cohort of patients with heart failure. sNEP has emerged as a new biomarker with promising implications for prognosis and therapy in patients with heart failure. Reducing the recurrent admission rate of heart failure patients has become an important target of public health planning strategies. Methods and ResultsWe measured sNEP levels in 1021 consecutive ambulatory heart failure patients. End points were the number of all‐cause, cardiovascular, and AHF hospitalizations during follow‐up. We used covariate‐adjusted incidence rate ratios to identify associations. At a median follow‐up of 3.4 years (interquartile range: 1.8–5.7), 391 (38.3%) patients died, 477 (46.7%) patients had 1901 all‐cause admissions, 324 (31.7%) patients had 770 cardiovascular admissions, and 218 (21.4%) patients had 488 AHF admissions. The medians for sNEP and amino‐terminal pro‐brain natriuretic peptide were 0.64 ng/mL (interquartile range: 0.39–1.22) and 1248 pg/mL (interquartile range: 538–2825), respectively. In a multivariate setting, the adjusted incidence rate ratios for the top (>1.22 ng/mL) versus the bottom (≤0.39 ng/mL) quartiles of sNEP were 1.37 (95% confidence interval: 1.03–1.82), P=0.032; 1.51 (95% confidence interval: 1.10–2.06), P=0.010; and 1.51 (95% confidence interval: 1.05–2.16), P=0.026 for all‐cause, cardiovascular, and AHF admissions, respectively. ConclusionsElevated sNEP levels predicted an increased risk of recurrent all‐cause, cardiovascular, and AHF admissions in ambulatory patients with heart failure.https://www.ahajournals.org/doi/10.1161/JAHA.117.005712heart failureneprilysinreadmission |
| spellingShingle | Julio Núñez Eduardo Núñez Jaume Barallat Vicent Bodí Gema Miñana M. Cruz Pastor Juan Sanchis Josep Lupón Antoni Bayes‐Genis Serum Neprilysin and Recurrent Admissions in Patients With Heart Failure Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease heart failure neprilysin readmission |
| title | Serum Neprilysin and Recurrent Admissions in Patients With Heart Failure |
| title_full | Serum Neprilysin and Recurrent Admissions in Patients With Heart Failure |
| title_fullStr | Serum Neprilysin and Recurrent Admissions in Patients With Heart Failure |
| title_full_unstemmed | Serum Neprilysin and Recurrent Admissions in Patients With Heart Failure |
| title_short | Serum Neprilysin and Recurrent Admissions in Patients With Heart Failure |
| title_sort | serum neprilysin and recurrent admissions in patients with heart failure |
| topic | heart failure neprilysin readmission |
| url | https://www.ahajournals.org/doi/10.1161/JAHA.117.005712 |
| work_keys_str_mv | AT julionunez serumneprilysinandrecurrentadmissionsinpatientswithheartfailure AT eduardonunez serumneprilysinandrecurrentadmissionsinpatientswithheartfailure AT jaumebarallat serumneprilysinandrecurrentadmissionsinpatientswithheartfailure AT vicentbodi serumneprilysinandrecurrentadmissionsinpatientswithheartfailure AT gemaminana serumneprilysinandrecurrentadmissionsinpatientswithheartfailure AT mcruzpastor serumneprilysinandrecurrentadmissionsinpatientswithheartfailure AT juansanchis serumneprilysinandrecurrentadmissionsinpatientswithheartfailure AT joseplupon serumneprilysinandrecurrentadmissionsinpatientswithheartfailure AT antonibayesgenis serumneprilysinandrecurrentadmissionsinpatientswithheartfailure |